Artiva Biotherapeutics, Inc. · NASDAQ:ARTV
Artiva Biotherapeutics — 17th International Symposium on Sjögren's Disease 2026
18 slides from Artiva Biotherapeutics's conference presentation, Sep 23, 2026
Slide 1: 17th International Symposium on Sjögren's Disease
17 1H INTERNATIONAL SYMPOSIUM SJOGREN’S DISEASE SEPTEMBER 29' - OCTOBER 2%? TH AMI . ea | Q MAISON INTERNATIONALE CITE UNIVERSITAIRE
Slide 2: AB-101 with Rituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease
AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined with Rituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease Guillermo Valenzuela, MD, FACR 1, Tamar Brionez, MD, CCD2, Norman B. Gaylis, MD, MACR, FACP3, Heather Raymon, PhD4, Lisa Guerrettaz, PhD4, Gi
Slide 3: Disclosures
Disclosures • Guillermo. Valenzuela, MD: AbbVie, Alexion, Amgen, Artiva Bio, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Centocor, Esaote, Exagen, Genentech, Gilead, Global Healthy Living Foundation, Horizon, Image Analysis Group, Janssen, Lilly, Mallinckrodt, Merck, Novartis, Pfizer, Pharmacia
Slide 4: AB-101 (AlloNK) in Sjögren Disease, a B-cell Driven Disease
AB-101 (AlloNK®) in Sjögren Disease (SjD), a B-cell Driven Disease Unmet Need: • Significant systemic manifestations may accompany characteristic dryness of the mouth and eyes • No approved therapies ➢ Current therapies include steroids, rituximab (RTX), and hyperimmune gamma globulin (IVIG) used of
Slide 5: AB-101 + Rituximab in Rheumatological Diseases
AB-101 + Rituximab (RTX) in Rheumatological Diseases Pathogenic AB-101 B-cell (NK cell) Low dose supportive cyclophosphamide (CY)/ fludarabine (FLU) conditioning B-cell CD16 Rejection Antigen (FcR) X • CD8/CD4 rejection • NK rejection (missing self) • HLA ab (ADCP- macrophage, ADCC- NK, B-cell targe
Slide 6: Complete B-Cell Depletion with AB-101 + RTX Across Autoimmune Diseases
Complete B-Cell Depletion with AB-101 + RTX Across Autoimmune Diseases Demonstrates B-cell Reset Uniform and consistent B-cell depletion observed by Day 13 in all 51 B-cell reconstitution with increase in patients with autoimmune diseases naïve/transitional B cells (n=13) • B-cell reconstitution aft
Slide 7: Basket Study: Design and Dosing
Basket Study: Design and Dosing Design: Ph2a study single-arm study of AB-101+ RTX in four B-cell dependent autoimmune diseases (RA; SjD; SSc; IIM). Dosing (All IV and outpatient): ➢ Conditioning: cyclophosphamide + fludarabine ➢ Rituximab: 1000 mg x 2 doses given 2 weeks apart ➢ AB-101 (each dose):
Slide 8: SjD Cohort: Demographics, Disease Severity
SjD Cohort: Demographics, Disease Severity • Number: First 11 subjects with at least 6-month follow-up • Disease characteristics: long-standing disease, high disease activity and refractory to SoC ❑ Age: Mean 53.6 years ❑ Sex: 100% female ❑ Disease duration: Mean 12.2 years ❑ Prior therapy: Refracto
Slide 9: Improvement in Clinical Scores – ClinESSDAI and ESSPRI
Improvement in Clinical Scores – ClinESSDAI and ESSPRI ClinESSDAI (change) Mean 14.6 (± 1.45) at baseline 0 -1 -2 (Mean ± SEM) -3 -4 -5 -6 -7 -8 -9 -10 0 6 Months N= 11 11 Dashed lines indicate minimal clinically important improvement 9
Slide 10: Improvement in Clinical Scores – ClinESSDAI and ESSPRI
Improvement in Clinical Scores – ClinESSDAI and ESSPRI ClinESSDAI (change) ESSPRI (change) Mean 14.6 (± 1.45) at baseline Mean 8.0 (± 0.43) baseline 0 0 -1 -2 -1 (Mean ± SEM) -3 -4 -2 -5 -6 -3 -7 -8 -4 -9 -10 -5 0 6 0 6 Months Months N= 11 11 N= 11 11 Dashed lines indicate minimal clinically importa
Slide 11: Improvement in Clinical Scores – ClinESSDAI and ESSPRI
Improvement in Clinical Scores – ClinESSDAI and ESSPRI ClinESSDAI (change) ESSPRI (change) ESSPRI at Week 24 – Mean 14.6 (± 1.45) at baseline Mean 8.0 (± 0.43) baseline response by domain (% with ≥ 1 point 0 0 improvement) -1 -2 -1 -3 -4 -2 -5 -6 -3 82% 73% -7 55% -8 -4 -9 -10 -5 0 6 0 6 Dryness Fat
Slide 12: Improvement in Patient-Reported Outcomes
Improvement in Patient-Reported Outcomes Min. Point Change for Response FACIT-F (fatigue) Mean 18.1 (± 2.9) baseline (severe fatigue) 18 16 14 +13.0 (Mean ± SEM) 12 10 8 6 Increase = Improvement 4 2 0 0 6 Months N 11 11 = Dashed lines indicate minimal clinically important improvement 12
Slide 13: Improvement in Patient-Reported and Functional Outcomes
Improvement in Patient-Reported and Functional Outcomes Min. Point Change for Response FACIT-F (change) Patient Global (change) Mean 18.1 (± 2.9) Mean 7.21 (± 0.82) baseline baseline (severe fatigue) 18 0.0 16 -0.5 14 -1.0 Decrease = Improvement (Mean ± SEM) +13.0 12 -1.5 10 -2.0 8 -2.5 6 -3.0 Incre
Slide 14: Improvement in Patient-Reported and Functional Outcomes
Improvement in Patient-Reported and Functional Outcomes Min. Point Change for Response FACIT-F (change) Patient Global (change) Stimulated Salivary Flow (SSF) Mean 18.1 (± 2.9) Mean 7.21 (± 0.82) baseline baseline (severe fatigue) 18 0.0 1.4 16 -0.5 1.2 Normal Salivation (Mean ± SEM) SSF > 1.0 14 -1
Slide 15: Most Common AEs Consistent With Those Seen With CY/FLU or RTX
Most Common AEs Consistent With Those Seen With CY/FLU or RTX Ph2a Basket Study Cohort (N=73)* • No CRS, ICANS, GvHD, or hypogammaglobulinemia¹ • SAEs: 11% (n=8); 2 with serious infections – gastroenteritis; pneumonia & wound infection; none related to AB-101 • No opportunistic infections; none of t
Slide 16: Very Low Hospitalization Rates Consistent with Ability to Treat in Outpatient Settings
Very Low Hospitalization Rates Consistent with Ability to Treat in Outpatient Settings Treatment Days Outpatient Treatment Day Hospitalization for AE Each Row Represents One Patient (n=73*) No hospitalizations for TEAEs related to AB-101 Only 2 hospitalized of 73 for TEAE in first 28 days • SjD: Deh
Slide 17: AB-101: Summary in Sjögren Disease (SjD)
AB-101: Summary in Sjogren Disease (SjD) • Novel, off the shelf, non-genetically modified, investigational, allogeneic NK cell therapy • Administered in an outpatient setting with a targeting antibody, rituximab (RTX) • Highly effective in a cohort of patients with severe SjD ➢ Rapid, clinically mea
Slide 18: Thank You to Our Patients and Their Families
Thank You to Our Patients and Their Families 18
Artiva Biotherapeutics — 17th International Symposium on Sjögren's Disease 2026 on 6ix